Makale detayı · 2011
Polyoxazoline Chemistry Properties and Applications in Drug Delivery
- Yıl
- 2011
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı Bioconjugate Chemistry
- Katalog eşleşmesi (ISSN) Bioconjugate Chemistry
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
OpenAlex · İngilizce
Polyoxazoline polymers with methyl (PMOZ), ethyl (PEOZ), and propyl (PPOZ) side chains were prepared by the living cationic polymerization method and purified by ion-exchange chromatography. The following properties of polyoxazoline (POZ) were measured: apparent hydrodynamic radius by aqueous size-exclusion chromatography, relative lipophilicity by reverse-phase chromatography, and viscosity by cone-plate viscometry. The PEOZ polymers of different molecular weights were first functionalized and then conjugated to model biomolecules such as bovine serum albumin, catalase, ribonuclease, uricase, and insulin. The conjugates of catalase, uricase, and ribonuclease were tested for in vitro activity using substrate-specific reaction methods. The conjugates of insulin were tested for glucose lowering activity by injection to naïve Sprague-Dawley rats. The conjugates of BSA were injected into New Zealand white rabbits and serum samples were collected periodically and tested for antibodies to BSA. The safety of POZ was also determined by acute and chronic dosing to rats. The results showed that linear polymers of POZ with molecular weights of 1 to 40 kDa can easily be made with polydispersity values below 1.10. Chromatography results showed that PMOZ and PEOZ have a hydrodynamic volume slightly lower than PEG; PEOZ is more lipophilic than PMOZ and PEG; and PEOZ is significantly less viscous than PEG especially at the higher molecular weights. When PEOZ was attached to the enzymes catalase, ribonuclease, and uricase, the in vitro activity of the resultant bioconjugates depended on the extent of protein modification. POZ conjugates of insulin lowered blood glucose levels for a period of 8 h when compared to 2 h for insulin alone. PEOZ, like PEG, was also able to successfully attenuate the immunogenic properties of BSA. The POZ polymers (10 and 20 kDa) are safe when administered intravenously to rats, and the maximum tolerated dose (MTD) was greater than 2 g/kg. Blood counts, serum chemistry, organ weights, and the histopathology of key organs were normal. These results conclude that POZ has the desired drug delivery properties for a new biopolymer.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
424 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 26 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’xxs disease - Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications 2017
- Rotigotine polyoxazoline conjugate SER 214 provides robust and sustained antiparkinsonian benefit 2013
- Tuning drug release from polyoxazoline-drug conjugates 2019
- Effect of side chain variation on surface and biological properties of poly(2-alkyl-2-oxazoline) multilayers 2019
- Layer-By-Layer Modified Superparamagnetic Iron Oxide Nanoparticles with Stimuli-Responsive Drug Release Properties 2019
- Poly(oxazolines) 2018
- Amphiphilic Polyoxazoline Copolymer-Imidazole Complexes as Tailorable Thermal Latent Curing Agents for One-Component Epoxy Resins 2023
- Polyoxazoline-modified graphene oxides with improved water and epoxy resin dispersibility and stability towards composite applications 2022
- Synthesis of poly(2-ethyl-2-oxazoline)-b-poly(ε-caprolactone) conjugates by a new modular strategy 2020
- Synthesis and Structure-Property Relationship of Amphiphilic Poly(2-ethyl-co-2-(alkyl/aryl)-2-oxazoline) Copolymers 2022